Comparative Pharmacology
Head-to-head clinical analysis: MICONAZOLE 7 versus NILSTAT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MICONAZOLE 7 versus NILSTAT.
MICONAZOLE 7 vs NILSTAT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Imidazole antifungal agent that inhibits fungal cytochrome P450 14α-demethylase, thereby blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
Nystatin binds to ergosterol in fungal cell membranes, forming pores that disrupt membrane integrity and cause leakage of intracellular contents, leading to fungal cell death.
Apply 200 mg (one full applicator) intravaginally once daily at bedtime for 7 days.
Topical: Apply 100,000 units/g cream or ointment to affected area twice daily. Oral suspension: 100,000 units/mL; 4-6 mL swish and swallow four times daily for 14 days. Oral tablets: 500,000 units; 1-2 tablets three times daily.
None Documented
None Documented
Terminal half-life 24-30 hours; prolonged in hepatic impairment
Not well-defined due to minimal systemic absorption following oral or topical administration; estimated to be <1 hour in systemic circulation if absorbed.
Primarily fecal (~50%) and renal (~<1% unchanged)
Primarily via feces as unchanged drug; negligible urinary excretion (<1%).
Category A/B
Category C
Antifungal
Antifungal